Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
103 hedge funds and large institutions have $389M invested in Paratek Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 32 increasing their positions, 14 reducing their positions, and 13 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 14
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
38% more capital invested
Capital invested by funds: $282M → $389M (+$107M)
12% more funds holding
Funds holding: 92 → 103 (+11)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
64% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $39.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.5M |
| 3 |
Millennium Management
New York
|
+$8.07M |
| 4 |
Renaissance Technologies
New York
|
+$4.79M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$8.86M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.18M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$1.92M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.73M |
| 5 |
DM
Deerfield Management
New York
|
-$1.54M |
PRTK Hedge Fund Activity: Q1 2017 in Review
103 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2017, worth a combined $389M — up 38% from $282M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PRTK positions and 13 closed out — a net gain of 16 holders — while 32 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $23.7M. The largest seller was Broadfin Capital, cutting an estimated $8.86M.
- 103 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2017, up from 92 in Q4 2016.
- Funds reported $389M of Paratek Pharmaceuticals, Inc. stock for Q1 2017, up 38% quarter-over-quarter.
- 29 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2017 and 13 closed out, a net change of +16 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $23.7M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2017 was Broadfin Capital, an estimated $8.86M sold.
Based on aggregated 13F filings for Q1 2017.